Clin Nucl Med. 2019 Feb;44(2):123-124. doi: 10.1097/RLU.0000000000002386.
We report a case of a 69-year-old woman with primary hyperoxaluria type I, who developed a severe hypercalcemia despite controlled secondary hyperparathyroidism. Bone scintigraphy showed diffuse increased uptake in axial and peripheral skeleton. F-FDG PET/CT showed countless striking hypermetabolic foci, interesting 2 types of lesions (joint calcifications and periosteal resorptions). Bone biopsy demonstrated inflammatory changes around many calcium oxalate crystals; hypercalcemia was then related to oxalate osteopathy. Immunotherapy with denosumab was thus initiated. Eighteen months later, a second PET/CT showed decreased F-FDG uptake, reflecting treatment efficacy on inflammatory reaction secondary to calcium oxalosis skeletal deposits.
我们报告了一例 69 岁女性,患有 I 型原发性高草酸尿症,尽管继发甲状旁腺功能亢进得到控制,但仍出现严重高钙血症。骨闪烁显像显示轴向和外周骨骼弥漫性摄取增加。F-FDG PET/CT 显示无数显著高代谢病灶,有趣的是 2 种类型的病变(关节钙化和骨膜吸收)。骨活检显示许多草酸钙晶体周围有炎症改变;高钙血症与草酸钙骨病有关。因此,开始用 denosumab 进行免疫治疗。18 个月后,第二次 PET/CT 显示 F-FDG 摄取减少,反映了对草酸钙沉积引起的骨病变炎症反应的治疗效果。